Home > Insider Trading > Filing (0001209191-21-050881)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1652130	Intellia Therapeutics Inc.	NTLA	In Vitro & In Vivo Diagnostic Substances (2835)	364785571

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1810882	David Lebwohl	C/O Intellia Therapeutics, Inc. 40 Erie Street; Suite 130 Cambridge MA 02139	Evp, Chief Medical Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-08-09	2,400	$12.62	3,191	No	4	M	Direct
Common Stock	Disposition	2021-08-09	2,400	$164.05	791	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2021-08-09	2,400	$0.00	2,400	$12.62

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
197,600		2030-05-04	No	4	M	Direct

Footnotes

The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
Includes 568 and 223 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2020 and June 30, 2021, respectively.
The stock option award was issued pursuant to the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan and had vested as to 62,500 shares as of August 9, 2021.